drugset / Trial / NCT05263219
DEB-TACE+HAIC vs. HAIC for Large HCC
Phase 3
Unknown
230 enrolled
Second Affiliated Hospital of Guangzhou Medical University
Affiliated Hospital of Guangdong Medical University · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabFirst People's Hospital of Foshan · collabHainan General Hospital · collabJiangmen Central Hospital · collabMaoming People's Hospital · collabZhongshan People's Hospital, Guangdong, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) plus hepatic artery infusion chemotherapy (HAIC) compared with HAIC alone for unresectable large hepatocellular carcinoma (HCC).
Timeline
- Start
- 2022-02-10
- Primary completion
- 2026-02-09
- Completion
- 2026-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirarubicin | Small molecule | 60 mg | Other |
| Comparator | Leucovorin | Small molecule | 400 mg/m2 | Other |
| Comparator | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Comparator | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Comparator | fluorouracil | Small molecule | 2400 mg/m2 | Other |